25% P=0.0002 REDUCTION in the total
number of hospitalizations for heart failure
Similar results observed in the higher risk
subgroup of patients with heart rate ≥75 bpm
at baseline1

Ivabradine or placebo on top of guideline-recommended therapy including ACE inhibitor,
β-blocker, mineralocorticoi receptor antagonist.

Effect of ivabradine on recurrent hospitalization for worsening heart failure (total-time approach).

1. Borer JS, et al. Eur Heart J. 2012;33(22):2813-2820.

you want to know more …